Srinivas Muvvala, MD, MPH
Associate Professor of PsychiatryCards
About
Research
Publications
2025
Collaborating Across the Globe: The Yale-University of Jordan International Interprofessional Addiction Education Program
Muvvala S, Minahan-Rowley R, Al-Khateeb Y, Abu-Dahab R, Khoshnood K, Wazaify M, Tetrault J. Collaborating Across the Globe: The Yale-University of Jordan International Interprofessional Addiction Education Program. Substance Abuse 2025, 46: 1013-1018. PMID: 40913374, DOI: 10.1177/29767342251331389.Peer-Reviewed Original ResearchYale School of MedicineSubstance use disordersTraining programJoint training programsHealth care workforceAddiction medicineInternational conference presentationsGlobal public health challengePublic health challengePeer-reviewed articlesCare workforcePublished peer-reviewed articlesInterprofessional educationTreatment gapTreating substance use disordersKern modelSchool of MedicineHealth challengesConference presentationsTraining workshopsTraining opportunitiesEducation programsPublic healthSubstance useTwo-year programPrenatal opioid exposure alters pain perception and increases long-term health risks in infants with neonatal opioid withdrawal syndrome
Radhakrishna U, Radhakrishnan R, Uppala L, Trivedi T, Prajapati J, Rawal R, Muvvala S, Bahado-Singh R, Sadhasivam S. Prenatal opioid exposure alters pain perception and increases long-term health risks in infants with neonatal opioid withdrawal syndrome. Frontiers In Pain Research 2025, 6: 1497801. PMID: 40313396, PMCID: PMC12043715, DOI: 10.3389/fpain.2025.1497801.Peer-Reviewed Original ResearchNeonatal opioid withdrawal syndromeOpioid-exposed infantsOpioid withdrawal syndromePain-related genesOpioid exposureWithdrawal syndromeChronic painEpigenetic changesMaternal opioid exposurePrenatal opioid exposureImprove pain managementIon channel functionIllumina Infinium Methylation EPIC BeadChipInfinium Methylation EPIC BeadChipAnalyzed DNA methylationUnexposed control subjectsLong-term health risksPain reliefPain perceptionPregnant womenGnRH secretionPlacental tissueMorphine addictionHealth of mothersControl subjectsNovel Elective Course on Substance Use for Pharmacy Students in Jordan
Wazaify M, Al-Khateeb Y, Khoshnood K, Muvvala S, Minahan-Rowley R, Abu-Dahab R, Tetrault J. Novel Elective Course on Substance Use for Pharmacy Students in Jordan. American Journal Of Pharmaceutical Education 2025, 89: 101399. PMID: 40158728, DOI: 10.1016/j.ajpe.2025.101399.Peer-Reviewed Original ResearchConceptsPharmacy studentsHealth professions studentsAverage knowledge scoreSubstance useProfessions studentsBachelor of Pharmacy studentsKnowledge scoresUndergraduate pharmacy studentsDoctor of pharmacyAssess knowledgeElective courseHarm reductionAddiction treatment programsJordanian pharmacistsAddiction medicineFree treatmentSite visitsPositive changesTreatment programsPharmacyLecture-style presentationStudents' attitudesAttitudesPeoplePharmacistsPreliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial
O’Malley S, Miranda R, Book S, Chun T, Liss T, Malcolm R, Muvvala S, Padovano H, Schacht J, Blackburn B, Diamond I, Ransom J, Ryan M, Falk D, Litten R. Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial. Alcohol And Alcoholism 2025, 60: agaf001. PMID: 39829301, PMCID: PMC11744046, DOI: 10.1093/alcalc/agaf001.Peer-Reviewed Original ResearchAlcohol use disorderAldehyde dehydrogenase 2 inhibitorUse disorderTreat alcohol use disorderCue reactivity sessionsCue-elicited cravingCue-induced cravingHuman laboratory studiesTreatment-seeking adultsAlcohol use disorder pharmacotherapiesAldehyde dehydrogenase 2Multisite clinical trialDose to placeboWeeks of medicationEffect size estimatesReactivation sessionDrinking outcomesGroup differencesCravingMeasured 1 weekEffect sizeCohen's dDouble-blindPreliminary effectivenessAlcohol consumption
2024
Availability of Medications for Opioid Use Disorder in US Psychiatric Hospitals
Cohen S, Beetham T, Fiellin D, Muvvala S. Availability of Medications for Opioid Use Disorder in US Psychiatric Hospitals. JAMA Network Open 2024, 7: e2444679. PMID: 39535800, PMCID: PMC11561693, DOI: 10.1001/jamanetworkopen.2024.44679.Peer-Reviewed Original ResearchPrenatal opioid exposure significantly impacts placental protein kinase C (PKC) and drug transporters, leading to drug resistance and neonatal opioid withdrawal syndrome
Radhakrishna U, Radhakrishnan R, Uppala L, Muvvala S, Prajapati J, Rawal R, Bahado-Singh R, Sadhasivam S. Prenatal opioid exposure significantly impacts placental protein kinase C (PKC) and drug transporters, leading to drug resistance and neonatal opioid withdrawal syndrome. Frontiers In Neuroscience 2024, 18: 1442915. PMID: 39238930, PMCID: PMC11376091, DOI: 10.3389/fnins.2024.1442915.Peer-Reviewed Original ResearchNeonatal opioid withdrawal syndromeNeonatal opioid withdrawal syndrome treatmentRegulation of drug transportersOpioid use disorderOpioid withdrawal syndromeProtein kinase CDrug transportATP-binding cassetteDrug resistanceWithdrawal syndromeSevere neonatal opioid withdrawal syndromeSolute carrierPrenatal opioid exposureOpioid-exposed infantsATP-binding cassette drug transportersLevels of ATP-binding cassetteIllumina Infinium MethylationEPIC arrayKinase CMethylation changesGastric acid secretionImprove treatment outcomesDrug-drug interactionsMaternal opioidsMaternal relapseInfinium MethylationEPIC arrayThe Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review
Jegede O, De Aquino J, Hsaio C, Caldwell E, Funaro M, Petrakis I, Muvvala S. The Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review. Journal Of Addiction Medicine 2024, 18: 499-510. PMID: 39356620, PMCID: PMC11449257, DOI: 10.1097/adm.0000000000001356.Peer-Reviewed Original ResearchNonmedical opioid useOpioid use disorderOpioid useWithdrawal symptomsTreatment outcomesSymptoms prior to treatmentUse disorderRisk of precipitated withdrawalLow-dose buprenorphineSynthetic opioidsPotency synthetic opioidsConclusions Current evidencePrecipitated withdrawalRisk of overdoseDosing strategiesPharmacological interactionsClinical significanceDecreased riskWeb of ScienceOpioidInclusion criteriaCurrent evidenceClinical implicationsMOUDPainPlacental cytochrome P450 methylomes in infants exposed to prenatal opioids: exploring the effects of neonatal opioid withdrawal syndrome on health horizons
Radhakrishna U, Sadhasivam S, Radhakrishnan R, Forray A, Muvvala S, Metpally R, Patel S, Rawal R, Vishweswaraiah S, Bahado-Singh R, Nath S. Placental cytochrome P450 methylomes in infants exposed to prenatal opioids: exploring the effects of neonatal opioid withdrawal syndrome on health horizons. Frontiers In Genetics 2024, 14: 1292148. PMID: 38264209, PMCID: PMC10805101, DOI: 10.3389/fgene.2023.1292148.Peer-Reviewed Original ResearchNeonatal opioid withdrawal syndromeOpioid withdrawal syndromePlacental tissueWithdrawal syndromeLong-term clinical implicationsPrenatal opioid exposureNOWS treatmentPrenatal opioidsOpioid exposureOpioid effectsOpioid usePharmacologic treatmentCYP genesControl mothersMultiple CYP genesValuable biomarkerClinical implicationsInfantsPersonalized treatmentOpioidsCytochrome P450 enzymesInfinium MethylationEPIC BeadChipTreatmentIllumina Infinium MethylationEPIC BeadChipSyndrome
2023
Long-Term Treatment of Opioid Use Disorder with Medications
Wolfgang A, Weimer M, Na P, Fiellin D, Muvvala S. Long-Term Treatment of Opioid Use Disorder with Medications. 2023, 631-661. DOI: 10.1093/oxfordhb/9780197618431.013.23.ChaptersOpioid use disorderMedical diseasesUse disordersChronic medical diseasesExtended-release naltrexoneLong-term treatmentCause mortalityOUD treatmentClinical outcomesOngoing treatmentOpioid overdoseTerm treatmentMedicationsPsychosocial outcomesAddiction treatmentDisease paradigmOutcomesTreatmentEvidence-based paradigmDiseaseDisordersNegative outcomesImproved retentionRemissionRelapsingThe Current Status of Medical Student Education on Opioids
Jegede O, Na P, Petrakis I, Muvvala S. The Current Status of Medical Student Education on Opioids. 2023, 121-138. DOI: 10.1093/oxfordhb/9780197618431.013.5.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News
News
- October 03, 2025
Opinion: Inpatient Psychiatry Treatment Programs Must Step Up to Integrate Opioid Use Disorder Treatment
- November 14, 2024
Why Do So Few U.S. Psych Hospitals Use Medications for Opioid Use Disorder?
- August 15, 2024Source: Journal of Addiction Medicine
The Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review
- June 21, 2024
Department of Psychiatry Honors Residents, Fellows, Faculty, Staff at 2024 Annual Commencement Ceremonies